CORONA Remedies is currently trading at Rs. 1400.75, up by 13.45 points or 0.97% from its previous closing of Rs. 1387.30 on the BSE.
The scrip opened at Rs. 1402.00 and has touched a high and low of Rs. 1415.05 and Rs. 1393.65 respectively. So far 2192 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1540.90 on 19-Jan-2026 and a 52 week low of Rs. 1336.95 on 23-Dec-2025.
Last one week high and low of the scrip stood at Rs. 1540.90 and Rs. 1380.10 respectively. The current market cap of the company is Rs. 8600.33 crore.
The promoters holding in the company stood at 69%, while Institutions and Non-Institutions held 4.64% and 26.37% respectively.
CORONA Remedies has secured Eurasian Economic Union - Good Manufacturing Practices (EAEU-GMP) Certification for its finished dosage facility situated at Bhayla, Gujarat. This certification paves the way for the company’s entry into five EAEU member nations -- Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan -- under a B2B business model.
It unlocks access to a pharmaceutical market estimated at $25 billion and aligns seamlessly with the company’s long-term vision of fostering sustainable international partnerships. EAEU-GMP certification further strengthens the company’s focus across its four key therapeutic pillars -- Women’s Health, Cardio-Diabetes, Pain Management, and Urology.
CORONA Remedies is primarily engaged in the business of manufacturing, trading and marketing of pharmaceutical products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1654.70 |
| Dr. Reddys Lab | 1232.00 |
| Cipla | 1229.60 |
| Zydus Lifesciences | 915.45 |
| Lupin | 2332.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: